Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML Via Suppression of Oxidative Phosphorylation and Purine Biosynthesis

Katie Hege Hurrish, Yongwei Su, Sandra Wiley, Zhanjun Hou, Jenna Carter, Hasini Kalpage, Maik Hüttemann, Holly Edwards, Lisa Polin, Jing Li, Jay Yang, Larry Matherly, Jeffrey W. Taub, Yubin Ge

Blood (2021) 138 (Supplement 1): 2238.

https://doi.org/10.1182/blood-2021-147004

Published: 2021

Journal Articles

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

Tristan Knight, MD, Xinan Qiao, BS, Jun Ma, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Kathryn White, Hai Lin, MD, Yue Wang, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2019) 134 (Supplement_1): 1262.

https://doi.org/10.1182/blood-2019-123793

Published: 2019

Journal Articles

Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia

Yongwei Su, Xinyu Li, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Katie Hege, Yu Fukuda, John D. Schuetz, PhD, Joshua E. Allen, PhD, Martin Stogniew, Varun Vijay Prabhu, BPharm, MS, PhD, Jeffrey W. Taub, MD, Hai Lin, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 3936.

https://doi.org/10.1182/blood-2018-99-116997

Published: 2018

Journal Articles

Inhibition of ATR Potentiates Acute Myeloid Leukemia Cells to the RNA Pol I Transcription Inhibitor CX-5461

Margaret Shatara, MD, Tingting Wang, Xinyu Li, Holly Edwards, BS, Jeffrey W. Taub, MD, Hai Lin, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 5224.

https://doi.org/10.1182/blood-2018-99-113937

Published: 2018

Journal Articles

Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia

Daniel A Luedtke, BS, Yongwei Su, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Hai Lin, MD, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 1361.

https://doi.org/10.1182/blood-2018-99-118372

Published: 2018

Journal Articles

Novel Therapy for FLT3-ITD Acute Myeloid Leukemia Utilizing the Combination of CUDC-907 and Gilteritinib

Tristan Knight, MD, Xinan Qiao, BS, Holly Edwards, BS, Hai Lin, MD, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 1427.

https://doi.org/10.1182/blood-2018-99-111177

Published: 2018

Journal Articles

Targeting PI3K, mTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML

Yongwei Su, Xinyu Li, Jianyun Zhao, Jun Ma, Shuang Liu, Holly Edwards, Jeffrey W. Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2017) 130 (Supplement 1): 1255.

https://doi.org/10.1182/blood.V130.Suppl_1.1255.1255

Published: 2017

Journal Articles

Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia

Daniel A Luedtke, BS, Yongwei Su, Holly Edwards, Hai Lin, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2017) 130 (Supplement 1): 3819.

https://doi.org/10.1182/blood.V130.Suppl_1.3819.3819

Published: 2017

Journal Articles

ONC213, a Novel Second Generation Analog of ONC201, Shows Promising Anti-Leukemic Activity Against AML Cells In Vitro and In Vivo

Yongwei Su, Xinyu Li, Holly Edwards, Joshua E. Allen, PhD, Martin Stogniew, Varun Vijay Prabhu, BPharm, MS, PhD, Jeffrey W. Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2017) 130 (Supplement 1): 3822.

https://doi.org/10.1182/blood.V130.Suppl_1.3822.3822

Published: 2017

Journal Articles

Combination of Venetoclax and CUDC-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo

Xinyu Li, Jun Ma, Yongwei Su, Jianyun Zhao, Holly Edwards, Yue Wang, Jay Yang, MD, Jeffrey W Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2016) 128 (22): 1571.

https://doi.org/10.1182/blood.V128.22.1571.1571

Published: 2016

Journal Articles

Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells

Jianyun Zhao, Xiaojia Niu, Holly Edwards, Yue Wang, Jeffrey W Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2015) 126 (23): 2469.

https://doi.org/10.1182/blood.V126.23.2469.2469

Published: 2015

Journal Articles

Binding of Released Bim to Mcl-1 Is Responsible for Resistance to ABT-199 Which Can be Overcome By Combination with Daunorubicin or Cytarabine in Acute Myeloid Leukemia Cells

Xiaojia Niu, Jianyun Zhao, Jun Ma, Chengzhi Xie, Holly Edwards, Guan Wang, J. Timothy Caldwell, Roland Chu, Zhihong Wang, MD PhD, Hai Lin, Jeffrey W Taub, MD, Yubin Ge, PhD

Blood (2015) 126 (23): 1265.

https://doi.org/10.1182/blood.V126.23.1265.1265

Published: 2015

Journal Articles

At Clinically Achievable Concentrations Obatoclax (GX15-070) Potentiates The Cytotoxic Effect Of Cytarabine On Acute Myeloid Leukemia Cells By Enhancing DNA Damage

Yubin Ge, PhD, Chengzhi Xie, Holly Edwards, J. Timothy Caldwell, Jeffrey Taub, MD

Blood (2013) 122 (21): 3829.

https://doi.org/10.1182/blood.V122.21.3829.3829

Published: 2013

Journal Articles

Inhibition of Histone Deacetylases 1 and 6 Enhances Ara-C-Induced Apoptosis In Pediatric Acute Myeloid Leukemia Cells

Xuelian Xu, Chengzhi Xie, Holly Edwards, Hui Zhou, Steven Buck, Larry Matherly, PhD, Jeffrey Taub, MD, Yubin Ge, PhD

Blood (2010) 116 (21): 3275.

https://doi.org/10.1182/blood.V116.21.3275.3275

Published: 2010

Journal Articles

Synergistic Antileukemic Interactions Between Valproic Acid and Cytarabine: A Potential Means to Improve the Treatment of Pediatric Acute Myeloid Leukemia.

Chengzhi Xie, Holly Edwards, Lisa Polin, Hui Zhou, Xuanlin Wang, Song Yang, Salvatore B LoGrasso, Steven Buck, Mark Stout, Jeffrey Rubnitz, MD, PhD, Larry Matherly, PhD, Jeffrey Taub, MD, Qun Yu, Yubin Ge, PhD

Blood (2009) 114 (22): 2084.

https://doi.org/10.1182/blood.V114.22.2084.2084

Published: 2009

Journal Articles

Overexpression of GATA1 Confers Chemotherapy Resistance in Pediatric Acute Megakaryocytic Leukemia.

Holly Edwards, Chengzhi Xie, Alan Dombkowski, Maggie Keller, Mark Stout, Steven Buck, Larry Matherly, PhD, Jeffrey Taub, MD, Yubin Ge, PhD

Blood (2009) 114 (22): 2039.

https://doi.org/10.1182/blood.V114.22.2039.2039

Published: 2009

Journal Articles

RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia

Holly Edwards, Chengzhi Xie, Katherine M. LaFiura, Alan A. Dombkowski, Steven A. Buck, Julie L. Boerner, Jeffrey W. Taub, Larry H. Matherly, Yubin Ge

Blood (2009) 114 (13): 2744–2752.

https://doi.org/10.1182/blood-2008-09-179812

Published: 2009

Includes: Supplemental data

NARROW

A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML Via Suppression of Oxidative Phosphorylation and Purine Biosynthesis

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia

Inhibition of ATR Potentiates Acute Myeloid Leukemia Cells to the RNA Pol I Transcription Inhibitor CX-5461

Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia

Novel Therapy for FLT3-ITD Acute Myeloid Leukemia Utilizing the Combination of CUDC-907 and Gilteritinib

Targeting PI3K, mTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML

Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia

ONC213, a Novel Second Generation Analog of ONC201, Shows Promising Anti-Leukemic Activity Against AML Cells In Vitro and In Vivo

Combination of Venetoclax and CUDC-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo

Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells

Binding of Released Bim to Mcl-1 Is Responsible for Resistance to ABT-199 Which Can be Overcome By Combination with Daunorubicin or Cytarabine in Acute Myeloid Leukemia Cells

At Clinically Achievable Concentrations Obatoclax (GX15-070) Potentiates The Cytotoxic Effect Of Cytarabine On Acute Myeloid Leukemia Cells By Enhancing DNA Damage

Inhibition of Histone Deacetylases 1 and 6 Enhances Ara-C-Induced Apoptosis In Pediatric Acute Myeloid Leukemia Cells

Synergistic Antileukemic Interactions Between Valproic Acid and Cytarabine: A Potential Means to Improve the Treatment of Pediatric Acute Myeloid Leukemia.

Overexpression of GATA1 Confers Chemotherapy Resistance in Pediatric Acute Megakaryocytic Leukemia.

RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only